Prior Authorization Checklist For GLP-1 Meds (Semaglutide, Tirzepatide)

March 2, 2026

If your GLP-1 prescription is "approved" by your doctor but "pending" with your insurance, you're in prior authorization limbo. Use this checklist to get the right paperwork submitted the right way, so you're not stuck paying full price or restarting the process (again).

What Prior Authorization Is And Why It Matters For GLP-1 Coverage

Prior authorization (PA) is the insurance company's required "yes" before they'll cover certain medications, especially high-cost drugs like GLP-1 receptor agonists.

That includes brand names you see everywhere:

Semaglutide (Ozempic®, Wegovy®)
Tirzepatide (Mounjaro®, Zepbound®)
Others in the class (like Trulicity®)

Here's the frustrating part: insurers often treat GLP-1s as two different categories depending on the label indication.

If it's being prescribed for type 2 diabetes, coverage is more common (still not guaranteed).
If it's being prescribed for weight loss, coverage is much more plan-dependent, and many plans exclude weight-loss meds entirely. On traditional Medicare, for example, weight-loss drugs are generally excluded from coverage, which influences how many other plans structure their benefits.

PA matters because it's not just a formality. It's the gatekeeper between you and:

Paying a typical copay/coinsurance vs. paying cash price
Starting therapy this month vs. waiting weeks
Staying on a stable dose vs. interruptions that can worsen side effects when you restart

When your PA is done well, it makes it easy for the reviewer to say "approved" because your request clearly matches the plan's medical-necessity criteria and formulary rules.

Common Reasons GLP-1 Prior Authorizations Get Denied

Most denials aren't about whether GLP-1s work. They're about mismatch, between what's submitted and what the plan requires.

Common denial triggers include:

No qualifying diagnosis or missing labs: For diabetes coverage, many plans want a clear type 2 diabetes diagnosis and supporting A1C results. Some also require evidence you tried metformin at an adequate dose for a set time (often around 3 months) unless you couldn't tolerate it.
Requested for weight loss when your plan excludes it: If your plan doesn't cover anti-obesity meds, a PA may be auto-denied no matter how compelling your health story is.
Diagnosis conflicts (or red flags): Type 1 diabetes, history of ketoacidosis, or certain significant GI conditions may lead to denial depending on the plan rules and what's documented.
Incomplete documentation: Missing BMI, missing weight history, missing prior attempts (diet/exercise or supervised programs), or no evidence of lifestyle adherence.
Administrative issues: Wrong drug NDC, wrong dose/quantity, missing ICD-10 codes, or requesting a non-preferred GLP-1 without documenting why the preferred option won't work.

If you take away one thing: most PAs fail on paperwork, not medicine. Which is annoying, but also fixable.

Before You Start: Verify Your Benefits And The Exact GLP-1 Being Requested

Before your clinician's office submits anything, you want to confirm two things: (1) what your plan covers and (2) exactly which GLP-1 your prescriber is requesting.

This step saves the most time because it prevents a common mistake: your doctor sends a PA for Drug A, but your plan only prefers Drug B (or only covers one indication).

Use this quick pre-flight checklist:

Check your plan formulary (member portal or pharmacy benefit manager site). Look for:
Is the medication covered at all?
Is it listed as preferred or non-preferred?
Does it require prior authorization?
Are there step therapy requirements (e.g., metformin first, or a preferred GLP-1 first)?
Confirm the requested product and indication:
Semaglutide for diabetes is typically Ozempic: semaglutide for chronic weight management is typically Wegovy.
Tirzepatide for diabetes is Mounjaro: for weight management, Zepbound.

Insurers can be picky about this because the criteria and coverage buckets can differ.

Ask about submission pathway:
Many clinics submit through CoverMyMeds or a payer portal.
Some still use fax (yes, really), which increases the odds something gets lost.
Look for quantity limits and dose caps:
Some plans limit pens per 28 days.
Some require that your titration schedule match the label.
Estimate your real cost:
Copay/coinsurance can change after deductible.
Manufacturer savings cards may help for some commercial plans (not all).

If you're in the research phase and worried about GI side effects once you do get approved, consider planning ahead. GLP-1s often change appetite, motility, and food tolerance. A lot of people do better with a structured approach (protein-forward, gentle fiber, lower-trigger meals). Resources like Casa de Sante's low FODMAP meal plans and digestive health tools are designed specifically for sensitive stomachs, including people navigating GLP-1 therapy, so you're not improvising when nausea or bloating shows up.

Medical Documentation Checklist Your Prescriber Should Include

Think of the PA reviewer as someone reading a file fast, looking for boxes to check. Your goal is to make your case obvious.

Below is what you want your prescriber to include (and what you can politely confirm is in the submission). You're not telling them how to practice medicine, you're making sure the chart reflects the reality of your health.

Diagnosis And Clinical Rationale (Weight, A1C, Comorbidities)

Your documentation should clearly state:

Your diagnosis and why a GLP-1 is medically necessary.
For type 2 diabetes: diagnosis of T2DM plus recent A1C (and often history of other meds, like metformin).
For weight-related indications (when covered): your BMI and related conditions.
Objective data that ties to plan criteria:
Recent weight and height (so BMI is defensible)
A1C value and date (for diabetes)
Blood pressure, lipids, fatty liver markers, sleep study results, whatever is relevant
Comorbidities that commonly strengthen medical necessity:
Cardiovascular disease (or high risk)
Obstructive sleep apnea (and whether you're using PAP/CPAP)
Metabolic dysfunction–associated steatotic liver disease (MASLD/MASH)
Prediabetes/insulin resistance markers (plan-dependent)

A small but important detail: ask your clinician to write the rationale in plain language and in insurance language. "High cardiometabolic risk, failed adequate lifestyle intervention, GLP-1 indicated to improve glycemic control and reduce risk" reads like a coverage criteria checklist, because it is.

Weight History, Prior Weight-Loss Attempts, And Lifestyle Program Details

Many plans want evidence you didn't just wake up yesterday and ask for a GLP-1.

Your file is stronger when it includes:

Weight timeline: weights/BMI documented across multiple visits (not just one snapshot)
Prior weight-loss attempts:
what you tried (calorie tracking, strength training plan, nutrition counseling, etc.)
how long you tried it
what happened (plateau, regain, intolerable hunger, etc.)
Lifestyle program participation (if required):
"6 months supervised diet/exercise program" comes up frequently in plan criteria
Documentation can include dietitian visits, program receipts, coaching notes, or clinic notes summarizing adherence

If you're actively working on lifestyle changes now, that counts too, just make sure it's documented. Even a brief note like "Patient adherent to high-protein nutrition plan and walking 150 minutes/week for 5 months with <2% weight change" is the kind of sentence that prevents avoidable denials.

Safety Screen: Contraindications, Risks, And Relevant Labs

Plans often want reassurance that a GLP-1 is safe for you.

Ask your clinician to document:

Contraindication screening:
Personal/family history of medullary thyroid carcinoma (MTC)
MEN2
Prior severe hypersensitivity
Significant GI disease concerns (plan-dependent)
Relevant baseline labs (as applicable):
A1C (again, date matters)
CMP (liver enzymes, kidney function)
Lipids
Sometimes TSH, depending on your history

Also: side effects are part of "safety." If you've previously had severe nausea/constipation on a GLP-1 and you're retrying with a slower titration, that rationale should be in the notes.

If your stomach is sensitive even without GLP-1s, get ahead of it. Many people do well with a "GI calm" approach: smaller meals, lower-FODMAP triggers, adequate electrolytes, and protein that's easy to digest. Casa de Sante's gut health supplements and GLP-1-friendly nutrition supports are built around that exact problem, keeping you consistent enough to actually benefit from the medication.

GLP-1 Prescription Details That Must Match The Formulary

This is where a lot of "denials" are really just clerical mismatches.

The prescription request should match:

Exact drug name (and correct product for indication)
Strength and dose (including titration schedule)
Directions (SIG) that align with labeling and plan rules
Quantity that matches the plan's limit (e.g., per 28 days)
Refills and duration (some plans want a specific timeframe)

If your plan prefers one GLP-1 over another, your prescriber may need to document:

trial and failure of the preferred agent, or
a reason you can't use it (e.g., intolerance, contraindication, shortage issues, plan-dependent)

One simple tactic: ask the office staff to read back what they're submitting, drug, dose, quantity, ICD-10. You'd be shocked how many denials disappear when that 60-second check happens.

What To Ask Your Clinician’s Office To Submit (And How To Follow Up)

You shouldn't have to be your own case manager… but you'll often get faster approval if you act like one (politely).

Here's what to ask for, specifically, and how to follow up without becoming that person.

Prior Authorization Form, Clinical Notes, And Supporting Attachments

Ask your clinician's office to submit a complete packet, not just the PA form.

Your "please include this" list:

The insurer's PA form (or the electronic equivalent via CoverMyMeds)
Recent office visit note that states:
diagnosis
BMI/weight
clinical rationale
prior therapies
lifestyle efforts
Lab reports (A1C, metabolic labs) with dates
Medication history showing prior meds tried (metformin, other agents, or prior GLP-1)
Any required program proof (dietitian notes, supervised weight program documentation)

A practical tip: ask for confirmation of the submission method, CoverMyMeds key, portal reference number, or fax confirmation sheet. That becomes your breadcrumb trail.

ICD-10, CPT, And Quantity Limits: Preventing Administrative Denials

Administrative denials feel personal, but they're usually a coding or limits problem.

Ask your clinician's office to double-check:

ICD-10 codes match the diagnosis being used for coverage
Example: type 2 diabetes is generally coded under E11.x (your exact code depends on details)
Any relevant CPT codes (if required by your plan for associated visits/services)
Quantity limits
The most common issue: requesting more pens than allowed per 28 days
Dose consistency
The prescription SIG should match the dose being requested on the PA

If your plan requires step therapy, your packet should explicitly show it was met:

"Tried metformin at maximum tolerated dose for ~3 months: A1C remains above goal," or
"Metformin intolerance documented (GI side effects), discontinued," etc.

Expected Timelines, Status Checks, And Refill/Reauthorization Planning

Timelines vary, but in many cases you'll see:

Initial decision within several business days (sometimes faster, sometimes painfully slower)
Requests for more information ("pending") if something's missing

How to stay on top of it without spiraling:

Day 2–3: Call the insurer or check your portal for PA status.
If pending: ask what exactly is missing (be specific, lab? chart note? step therapy proof?).
If approved: ask how long the approval lasts.

Many plans require reauthorization every 6–12 months. Planning ahead prevents a gap in therapy:

Put a reminder on your calendar 60 days before the PA expires.
Ask your clinician what success metric your plan cares about:
improved A1C for diabetes coverage
documented weight change or maintenance for obesity coverage (when applicable)
Make sure follow-up visits and weights/labs are documented.

And yes, refill timing matters. If you're dealing with nausea, constipation, or reflux on GLP-1s, consistency plus a gentler meal strategy often helps you stay on schedule long enough to show results. That's where targeted digestive support and simplified meal planning (like the GLP-1-friendly options at Casa de Sante) can be more than "nice to have", it can make adherence realistic.

If You Get Denied: Step-By-Step Appeals Checklist

A denial isn't the end. It's usually a request for a different format of proof.

The trick is to treat the denial like a to-do list, not a verdict.

How To Read The Denial Letter And Identify The Fix

When you get the denial letter (or portal message), look for:

The exact denial reason (missing information vs. not covered vs. criteria not met)
The policy criteria they're using (sometimes attached, sometimes summarized)
The deadline to appeal
Where and how to submit the appeal

Common "fixable" denial reasons and what to gather:

"No documentation of metformin trial" → pharmacy fill history, chart note addendum, intolerance documentation
"BMI not documented" → visit note with height/weight: problem list update
"Insufficient lifestyle trial" → dietitian notes, program documentation, clinician letter summarizing duration/adherence
"Non-preferred GLP-1 requested" → documentation of failure/intolerance of preferred option

If the letter says "plan exclusion" (weight-loss meds not covered), you can still ask about exceptions, but it's a different kind of fight, and sometimes the best move is switching to a covered indication/medication strategy if clinically appropriate.

First-Level Appeal, Peer-To-Peer Review, And External Review Options

Work in this order so you don't miss steps:

First-level appeal (internal appeal)

Submit a clear appeal letter (often written by your clinician) plus the missing documents.
Keep it tight: diagnosis, criteria met, supporting labs, prior therapy, why this drug/dose.

Peer-to-peer review

Your prescriber speaks directly with the insurer's clinician reviewer.
This is especially useful when the denial is based on "medical necessity" rather than missing paperwork.

External review

If your plan allows it, you can request an independent external review after internal appeals.

Your personal checklist to keep things moving:

Ask the clinic: "Who is handling the appeal, and when will it be submitted?"
Ask the insurer: "What documents would change this decision?"
Keep copies of everything (denial letter, appeal packet, fax confirmations, portal screenshots)

One extra angle that's often overlooked: if side effects are part of the reason you can't use a preferred drug, that should be documented clearly. "Intolerable GI adverse effects even though dose reduction and antiemetic trial" is more persuasive than "couldn't tolerate."

And if GLP-1 GI symptoms are threatening adherence during this process, stabilize the basics: hydration, electrolytes, protein you can tolerate, and trigger-aware meals. That's the difference between "I had to stop" and "I stayed on it long enough to prove it works."

Special Situations: Switching GLP-1s, Dose Escalation, And Menopause-Related Considerations

Real life rarely fits a neat PA checkbox. These are the situations where your documentation needs to tell a clear story, fast.

From One GLP-1 To Another: Continuity-Of-Care Documentation

Switches happen for all kinds of reasons:

side effects
plateau
supply issues
formulary changes
changing from diabetes indication to weight management (or vice versa)

For a smoother PA, ask your clinician to document continuity-of-care details:

Which GLP-1 you used, dose, and dates
Your response (A1C improvement, weight change, appetite control)
Why you're switching (ineffectiveness, intolerance, access)
Why the requested GLP-1 is the most appropriate next option

If your plan has "preferred" GLP-1s, this is where you show you're not shopping, you're sequencing therapy logically.

Dose Increases And Maintenance Dosing: How To Document Medical Necessity

Dose escalation is a common place where claims get stuck, especially if the quantity/dose doesn't match the plan's expectation.

To support dose increases, your documentation should include:

Confirmation you completed titration as directed (or why you needed a slower schedule)
Evidence of benefit:
improved A1C or glucose trends
clinically meaningful weight loss (some criteria reference ~5% weight loss, but it's plan-specific)
Evidence you're continuing lifestyle measures (diet, activity, program participation)
Any side effects and how they're being managed

Maintenance dosing can also require reauthorization. Make it easy for the reviewer:

show starting weight, current weight, and trajectory
show that stopping would risk regain or loss of glycemic control

If you're in the "maintenance but my stomach is still touchy" camp, this is also where consistency matters. A predictable meal plan and gut-friendly supplementation can help you stay stable, which helps your documentation look stable too.

Perimenopause/Menopause, Metabolic Risk, And Hormone Therapy Notes To Include

Perimenopause and menopause can make GLP-1 coverage conversations feel extra complicated, because your body changes, your risk profile changes, and sometimes your chart doesn't reflect that clearly.

There usually aren't special "menopause-only" PA criteria. So the strategy is to connect menopause-related changes to recognized metabolic risks your plan already cares about.

Ask your clinician to include notes like:

Your menopausal status (perimenopause/menopause) and relevant symptoms (sleep disruption, hot flashes) when they affect weight/metabolic health
Cardiometabolic risk factors:
rising A1C/prediabetes markers
worsening lipids
blood pressure trends
central adiposity/waist changes (if documented)
Comorbidities such as OSA, MASLD/MASH, or elevated cardiovascular risk
If you're using hormone therapy (HT):
that it's being monitored
no contraindication issues relevant to the GLP-1 request

If you're trying to coordinate GLP-1 therapy with hormone shifts and GI sensitivity, a "one-plan" approach beats scattered advice. This is where targeted resources, like Casa de Sante's GLP-1-aware digestive supports and meal planning, can reduce trial-and-error while you and your clinician focus on the medical necessity case your insurer needs.

Conclusion

If you want your GLP-1 prior authorization approved, the winning move is boring: make your chart impossible to misunderstand. Clear diagnosis, dated labs, documented prior therapy, correct dosing/quantity, and a clean paper trail for follow-up.

Print (or copy) the checklists above into a note on your phone, then do one thing today: message your clinician's office and ask what they still need from you, recent labs, weight history, program documentation, or pharmacy records. When you close those gaps early, you usually avoid the denial-and-appeal loop.

And once coverage is handled, protect your momentum. The easier it is to tolerate the medication, especially through titration, the easier it is to stay consistent long enough to show results your plan will reauthorize. That's the not-so-secret part nobody puts in the PA form.

Frequently Asked Questions: Prior Authorization Checklist for GLP-1 Meds

What is a prior authorization checklist for GLP-1 meds, and why does it matter?

A prior authorization checklist for GLP-1 meds helps you ensure your insurer gets the exact documentation needed to approve coverage for drugs like Ozempic, Wegovy, Mounjaro, or Zepbound. A complete PA can mean a normal copay instead of cash price and prevents delays, denials, and therapy interruptions.

What are the most common reasons GLP-1 prior authorization requests get denied?

Most GLP-1 PA denials are paperwork mismatches, not clinical disagreement. Common triggers include missing Type 2 diabetes diagnosis or recent A1C labs, no proof of metformin trial/intolerance (often ~3 months), requesting weight-loss coverage when the plan excludes it, missing BMI/weight history, or wrong dose, NDC, or ICD-10 codes.

What documents should my doctor include to pass a GLP-1 prior authorization checklist?

A strong PA packet usually includes the insurer PA form (often via CoverMyMeds), a recent visit note with diagnosis and clinical rationale, dated labs (like A1C and metabolic labs), BMI/weight history, prior medication history (e.g., metformin or preferred GLP-1 trials), lifestyle program details (often 6 months if required), and contraindication screening (MTC/MEN2, severe GI issues).

How do I verify my insurance benefits before submitting a prior authorization for GLP-1 meds?

Check your plan formulary or PBM portal to confirm the exact GLP-1 is covered, whether it’s preferred vs non-preferred, and if prior authorization or step therapy applies. Confirm the product matches the indication (Ozempic vs Wegovy; Mounjaro vs Zepbound), review quantity limits per 28 days, and ask how the PA will be submitted (portal, CoverMyMeds, or fax).

How long does a GLP-1 prior authorization take, and how often is reauthorization required?

Timelines vary by plan, but many initial decisions arrive within several business days, with “pending” status if information is missing. Many insurers require reauthorization every 6–12 months. Plan ahead by tracking the approval end date and ensuring follow-up weights and/or A1C results are documented so the next PA can prove ongoing benefit.

If my GLP-1 prior authorization is denied, what’s the best way to appeal?

Start by reading the denial letter for the exact reason (missing info, criteria not met, or plan exclusion) and the appeal deadline. Fix what’s missing—metformin fill history, BMI documentation, lifestyle program proof, or preferred-drug trial details—then submit a first-level appeal. If needed, request a peer-to-peer review, and pursue external review when available.